戻る Agenda
Informing Development and Authorizations Using Real World Evidence/Artificial Intelligence
Session Chair(s)
Lawrence Liberti, PHD, RAC
Director, D.K. Kim International Center for Regulatory Science
The Kim Center/ USC DRQS, United States
The evolution of actionable insights on how medicines are used, generated from real world evidence and artificial intelligence will be discussed. This session will focus on knowledge management, regulatory intelligence, and learning healthcare systems.
Learning Objective : Discuss the potential for artifical intelligence and real world evidence to inform both development and authorization; Identify the opportunities and barriers and how AI and RWE in conjunction with knowledge management can enable better development and regulatory decisions.
Speaker(s)
How Do Companies View Knowledge Management as a Decision-Making Tool?
Magda Bujar, PHD, MSC
Centre for Innovation in Regulatory Science (CIRS), United Kingdom
Associate Director, Regulatory Programme and Strategic Partnerships
Learning Healthcare Systems: Managing Real World Evidence/Knowledge - How Can This Transition Healthcare Data to Actionable Information?
Andrea Julsing Keyter, MS
South African Health Products Regulatory Authority, South Africa
Deputy Director, Medical Devices
Potential Uses of AI for Regulatory Intelligence: How Can This be Used Practically and What are the Barriers and Opportunities?
Mukesh Singhal, MBA
Deloitte, United States
Partner